Quantinno Capital Management LP Acquires 48,554 Shares of Fresenius Medical Care AG (NYSE:FMS)

Quantinno Capital Management LP boosted its holdings in shares of Fresenius Medical Care AG (NYSE:FMS) by 78.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 110,078 shares of the company’s stock after purchasing an additional 48,554 shares during the quarter. Quantinno Capital Management LP’s holdings in Fresenius Medical Care were worth $2,345,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Creative Planning raised its stake in Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after purchasing an additional 6,373 shares during the period. Wulff Hansen & CO. raised its stake in Fresenius Medical Care by 1,809.0% during the 2nd quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the period. Marshall Wace LLP raised its stake in Fresenius Medical Care by 8.5% during the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock valued at $293,000 after purchasing an additional 1,207 shares during the period. Moran Wealth Management LLC raised its stake in Fresenius Medical Care by 47.0% during the 3rd quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the period. Finally, AQR Capital Management LLC bought a new stake in Fresenius Medical Care during the 2nd quarter valued at approximately $197,000. Institutional investors own 8.37% of the company’s stock.

Analysts Set New Price Targets

FMS has been the topic of a number of research reports. Berenberg Bank initiated coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective on the stock. Truist Financial lifted their price objective on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. Finally, StockNews.com initiated coverage on Fresenius Medical Care in a research note on Thursday, November 28th. They issued a “strong-buy” rating on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $24.30.

Fresenius Medical Care Stock Performance

NYSE FMS opened at $23.91 on Wednesday. The company has a market cap of $14.03 billion, a P/E ratio of 19.75, a P/E/G ratio of 0.98 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The business’s 50 day moving average price is $21.29 and its 200-day moving average price is $20.39. Fresenius Medical Care AG has a fifty-two week low of $17.93 and a fifty-two week high of $24.31.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.